Modality
Degrader
MOA
PCSK9i
Target
KRASG12D
Pathway
Checkpoint
Gastric Ca
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
~Dec 2020
→ ~Mar 2022
Phase 3
~Jun 2022
→ ~Sep 2023
NDA/BLA
Dec 2023
→ Apr 2031
NDA/BLACurrent
NCT08917086
1,489 pts·Gastric Ca
2023-12→2031-04·Completed
1,489 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-225.1y awayPh3 Readout· Gastric Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2031-04-22 · 5.1y away
Gastric Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08917086 | NDA/BLA | Gastric Ca | Completed | 1489 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Cevitinib | Regeneron | Phase 3 | FGFR |